Literature DB >> 15857982

Human rhinovirus type 89 variants use heparan sulfate proteoglycan for cell attachment.

Markete Vlasak1, Irene Goesler, Dieter Blaas.   

Abstract

We have previously isolated mutants of the major-group human rhinovirus type 89 that grow in cells deficient in intercellular adhesion molecule 1 (ICAM-1), the receptor used by the wild-type virus for cell entry [A. Reischl, M. Reithmayer, G. Winsauer, R. Moser, I. Goesler, and D. Blaas., J. Virol. 75:9312-9319, 2001]. We now demonstrate that one of these variants utilizes heparan sulfate proteoglycan (HSPG) as a cellular receptor. Adaptation to ICAM-1-deficient cells not only resulted in the newly acquired receptor specificity but also rendered the virus less stable at low pH and at elevated temperatures. This instability might compensate for the absence of the uncoating activity of ICAM-1. Whereas wild-type virus infection via ICAM-1 proceeded in the presence of the vesicular H(+)-ATPase inhibitor bafilomycin A1, infection by the mutant via HSPG was prevented by the drug. This suggests that the low pH prevailing in endosomal compartments is required for uncoating in the absence of the catalytic activity of ICAM-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15857982      PMCID: PMC1091682          DOI: 10.1128/JVI.79.10.5963-5970.2005

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  63 in total

Review 1.  Evolution of cell recognition by viruses.

Authors:  E Baranowski; C M Ruiz-Jarabo; E Domingo
Journal:  Science       Date:  2001-05-11       Impact factor: 47.728

2.  Kinetic analysis of the effect of poliovirus receptor on viral uncoating: the receptor as a catalyst.

Authors:  S K Tsang; B M McDermott; V R Racaniello; J M Hogle
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

3.  Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice.

Authors:  K A Bernard; W B Klimstra; R E Johnston
Journal:  Virology       Date:  2000-10-10       Impact factor: 3.616

4.  Human papillomavirus infection requires cell surface heparan sulfate.

Authors:  T Giroglou; L Florin; F Schäfer; R E Streeck; M Sapp
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

5.  Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection.

Authors:  L K Hallak; D Spillmann; P L Collins; M E Peeples
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

6.  Passage of classical swine fever virus in cultured swine kidney cells selects virus variants that bind to heparan sulfate due to a single amino acid change in envelope protein E(rns).

Authors:  M M Hulst; H G van Gennip; R J Moormann
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Comparison of heparin-sensitive attachment of pseudorabies virus (PRV) and herpes simplex virus type 1 and identification of heparin-binding PRV glycoproteins.

Authors:  D Sawitzky; H Hampl; K O Habermehl
Journal:  J Gen Virol       Date:  1990-05       Impact factor: 3.891

8.  Human rhinovirus HRV14 uncoats from early endosomes in the presence of bafilomycin.

Authors:  N Bayer; E Prchla; M Schwab; D Blaas; R Fuchs
Journal:  FEBS Lett       Date:  1999-12-10       Impact factor: 4.124

9.  Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans.

Authors:  Isidoro Martínez; José A Melero
Journal:  J Gen Virol       Date:  2000-11       Impact factor: 3.891

Review 10.  Heparan sulfate: decoding a dynamic multifunctional cell regulator.

Authors:  J Turnbull; A Powell; S Guimond
Journal:  Trends Cell Biol       Date:  2001-02       Impact factor: 20.808

View more
  32 in total

Review 1.  Viral quasispecies evolution.

Authors:  Esteban Domingo; Julie Sheldon; Celia Perales
Journal:  Microbiol Mol Biol Rev       Date:  2012-06       Impact factor: 11.056

Review 2.  Clinical and molecular features of human rhinovirus C.

Authors:  Yury A Bochkov; James E Gern
Journal:  Microbes Infect       Date:  2012-01-12       Impact factor: 2.700

3.  Single Neutralizing Monoclonal Antibodies Targeting the VP1 GH Loop of Enterovirus 71 Inhibit both Virus Attachment and Internalization during Viral Entry.

Authors:  Zhiqiang Ku; Xiaohua Ye; Jinping Shi; Xiaoli Wang; Qingwei Liu; Zhong Huang
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

4.  Human rhinovirus type 54 infection via heparan sulfate is less efficient and strictly dependent on low endosomal pH.

Authors:  Abdul Ghafoor Khan; Johannes Pichler; Anke Rosemann; Dieter Blaas
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

5.  Mutations in VP1 and 3A proteins improve binding and replication of rhinovirus C15 in HeLa-E8 cells.

Authors:  Yury A Bochkov; Kelly Watters; Sarmila Basnet; Shakher Sijapati; Marchel Hill; Ann C Palmenberg; James E Gern
Journal:  Virology       Date:  2016-10-13       Impact factor: 3.616

6.  N- and 6-O-sulfated heparan sulfates mediate internalization of coxsackievirus B3 variant PD into CHO-K1 cells.

Authors:  Andreas E Zautner; Birgit Jahn; Elke Hammerschmidt; Peter Wutzler; Michaela Schmidtke
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

7.  Polyamine Depletion Abrogates Enterovirus Cellular Attachment.

Authors:  Thomas M Kicmal; Patrick M Tate; Courtney N Dial; Jeremy J Esin; Bryan C Mounce
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 8.  Rhinoviruses and Their Receptors.

Authors:  Sarmila Basnet; Ann C Palmenberg; James E Gern
Journal:  Chest       Date:  2019-01-17       Impact factor: 9.410

Review 9.  Rhinoviruses and Their Receptors: Implications for Allergic Disease.

Authors:  Yury A Bochkov; James E Gern
Journal:  Curr Allergy Asthma Rep       Date:  2016-04       Impact factor: 4.806

10.  Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor.

Authors:  Chee Wah Tan; Chit Laa Poh; I-Ching Sam; Yoke Fun Chan
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.